News

Support the ALS cause and raise critical funds for a future without ALS On Sunday, September 24, cyclists will come together to gear up for change at the third annual ALS Canada Revolution Ride in Dundas, Ontario. Participants…

The ALS Society of Canada (ALS Canada) and the Kevin Daly Bursary Fund are pleased to announce the recipients of the 2023 ALS Canada Kevin Daly Bursary, granted to post-secondary students who share a personal connection to amyotrophic lateral sclerosis…

Pull to End ALS – a unique fundraiser to support people and families living with ALS On Saturday, September 16, the ALS community will come together to “pull” for change at the ALS Canada Pull to End…

In March 2023, the ALS Society of Canada and Brain Canada announced the latest round of Discovery Grant recipients from their 2022 research grant competition. With support from SLA Québec and the Dr. Jean-Pierre Canuel Fund, nine Canadian researchers and…

In March 2023, the ALS Society of Canada and Brain Canada announced the latest round of Discovery Grant recipients from their 2022 research grant competition. With support from SLA Québec and the Dr. Jean-Pierre Canuel Fund, nine Canadian researchers and…

The province of Ontario has listed RADICAVA Oral Suspension (edaravone), also known as oral edaravone, on the public formulary as a therapy accessible through the Ontario Drug Benefit Program’s Exceptional Access Program (EAP) as a treatment for ALS. This decision…

ALS researchers from around the world continue to build upon existing work and make new discoveries in the hopes of realizing a future without ALS. In the July 2023 Research Update, you’ll learn about the role genetic factors may play…

Last updated: November 7, 2023 July 20, 2023 – Mitsubishi Tanabe Pharma Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) have successfully concluded negotiations for RADICAVA Oral Suspension (edaravone), also known as oral edaravone, and entered into a Letter of Intent…